Skip to main content
Arjan Diepstra
dr.

As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.

Clinical outcome and humoral immune responses of β-thalassemia major patients with severe iron overload to SARS-CoV-2 infection and vaccination: a prospective cohort study
Published in: EClinicalMedicine
Access to document 10.1016/j.eclinm.2023.102096 document
BackgroundCOVID-19 has raised special concern for patients with β-thalassemia major (β-TM) due to frequent comorbidities, regular blood transfusions, and iron overload. However, the exact implications of COVID-19 for patients with β-TM remain uncertain. We aimed to explore the COVID-19 incidence and severity, and the serological response to SARS-CoV-2 infection and vaccination in patients with β-TM.MethodsPatients with β-TM (n = 105) and age-matched healthy controls, all individuals of all control groups were health care workers of the hospital, were prospectively enrolled at the haematology department of Al-Shifa hospital in...
Hussam Ghoti, Hala Zreid, Israa Ghoti, Arno R. Bourgonje, Arjan Diepstra, Harry van Goor, Irit Avivi, Hisham Jeadi, Larissa E. van Eijk, Günter Weiss
Long non-coding RNAs associated with transcriptomic signatures and treatment outcome in diffuse large B-cell lymphoma
Published in: British Journal of Haematology
Access to document 10.1111/bjh.18870 document
Gerben Duns, Melanie Winkle, Lauren Chong, Daisuke Ennishi, Ryan D Morin, Arjan Diepstra, David W Scott, Joost L Kluiver, Christian Steidl, Anke van den Berg
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia.
Published in: Leukemia
Access to document 10.1038/s41375-023-01962-5 document
Correction to: Leukemia, published online 22 June 2022 At the time of original publication, there was an incomplete listing of contributing authors and their institutions. This revision corrects those omissions.
the International Agency for Research on Cancer/World Health Organization, Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D. Attygalle, Iguaracyra Barreto de Oliveira Araujo, Emilio Berti, Govind Bhagat, Anita Maria Borges, Daniel Boyer, Mariarita Calaminici, Amy Chadburn, John K.C. Chan, Wah Cheuk, Wee Joo Chng, John K. Choi, Shih Sung Chuang, Sarah E. Coupland, Magdalena Czader, Sandeep S. DaveDaphne de Jong, Arianna Di Napoli, Ming Qing Du, Kojo S. Elenitoba-Johnson, Judith Ferry, Julia Geyer, Dita Gratzinger, Joan Guitart, Sumeet Gujral, Marian Harris, Christine J. Harrison, Sylvia Hartmann, Andreas Hochhaus, Patty M. Jansen, Kennosuke Karube, Werner Kempf, Joseph Khoury, Hiroshi Kimura, Wolfram Klapper, Alexandra E. Kovach, Shaji Kumar, Alexander J. Lazar, Stefano Lazzi, Lorenzo Leoncini, Nelson Leung, Vasiliki Leventaki, Xiao Qiu Li, Megan S. Lim, Wei Ping Liu, Abner Louissaint, Arjan Diepstra
Heparin-resistance in AL amyloidosis: a case report
Published in: BMC Anesthesiology
Access to document 10.1186/s12871-023-02147-4 document
BACKGROUND: Non-AT-III mediated heparin-resistance during CPB occurs by complex-forming with heparin-binding proteins. Currently, there are no specific recommendations for non-AT-III mediated heparin-resistance. CASE PRESENTATION: We present a fatal case of a 70-yr-old male-patient undergoing cardiac-surgery in which refractory heparin-resistance was observed. The massive AL amyloidosis found at autopsy is thought to be responsible and illustrates that awareness and knowledge of the etiology and perioperative strategies of non-AT-III mediated heparin-resistance is important. CONCLUSION: For anticoagulation during cardiopulmonary bypass surgery in case of a non-AT-III medicated heparin resistance, we refer...
Elisabeth S van Ede, Marlijn P A Hoeks, Jan Hofland, Vera D Linssen, Toin H van Kuppevelt, Elly M Versteeg, Theo G Hafmans, Arjan Diepstra, Benno Kusters, Sanne M M Vermorgen
M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism
Published in: Science Advances
Access to document 10.1126/sciadv.adf8522 document
It is increasingly becoming clear that cancers are a symbiosis of diverse cell types and tumor clones. Combined single-cell RNA sequencing, flow cytometry, and immunohistochemistry studies of the innate immune compartment in the bone marrow of patients with acute myeloid leukemia (AML) reveal a shift toward a tumor-supportive M2-polarized macrophage landscape with an altered transcriptional program, with enhanced fatty acid oxidation and NAD+ generation. Functionally, these AML-associated macrophages display decreased phagocytic activity and intra–bone marrow coinjection of M2 macrophages together with leukemic blasts strongly enhances in vivo transformation...
Isabel Weinhäuser, Diego A. Pereira-Martins, Luciana Y. Almeida, Jacobien R. Hilberink, Douglas R.A. Silveira, Lynn Quek, Cesar Ortiz, Cleide L. Araujo, Thiago M. Bianco, Antonio Lucena-Araujo, Jose Mauricio Mota, Shanna M. Hogeling, Dominique Sternadt, Nienke Visser, Arjan Diepstra, Emanuele Ammatuna, Gerwin Huls, Eduardo M. Rego, Jan Jacob Schuringa